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stroke care would prevent stroke-related death in 25,000
patients, serious disability in 71,000, and nursing home admis-
sion in 25,000. Despite the costs associated with such a program,
the net savings in health care costs over a 20-year period would
amount to Can$12 billion. CONCLUSION: Implementing
proven stroke therapies and practices across Canada will result
in signiﬁcant improvements in both lives and health care costs.
Analyses based on this model will support national and provin-
cial stroke strategies appropriate to their needs and resources.
PST4
COST-EFFECTIVENESS OF RECOMBINANT ACTIVATED
FACTOR VII IN THE TREATMENT OF INTRACEREBRAL
HEMORRHAGE OVER A TWO-YEAR MANAGED CARE
ENROLLMENT PERIOD
Earnshaw SR1,Wilson MR1, Joshi AV2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo
Nordisk Inc, Princeton, NJ, USA
OBJECTIVES: To estimate cost-effectiveness of rFVIIa com-
pared to standard care in treating ICH over an average MCO
enrollment period of two years from a third-party payer per-
spective. METHODS: A decision-analytic model estimating cost-
effectiveness of rFVIIa 80 mcg/kg compared to standard care in
treating ICH was adapted to measure cost-effectiveness over a
time horizon (enrollment period) of two years. Input parameters
were obtained from clinical trial, claims data, and published lit-
erature. Cost of rFVIIa was based on wholesale acquisition cost.
Costs were in 2006 US dollars. Outcomes included life-years and
quality-adjusted life years (QALY). In addition, population char-
acteristics were considered, including age (over/under 65) and
gender comparisons. One-way and multivariable sensitivity
analyses were conducted to assess robustness. RESULTS: Assum-
ing a cost-effectiveness threshold of $50,000 QALY, the incre-
mental cost-effectiveness ratio (ICER) showed rFVIIa to be
cost-effective compared to standard care alone ($2924/QALY
gained). Use of rFVIIa was found to be cost-effective in both the
under- and over-65 populations ($532/QALY gained and
$5323/QALY gained, respectively). Results did not differ sub-
stantially across gender. Results were robust to changes in model
parameters. CONCLUSION: Treating ICH with rFVIIa 80 mcg/
kg within an MCO is cost-effective over the average patient
enrollment period of two years compared to standard care. Due
to potential improvements in long-term clinical outcome, treat-
ment with rFVIIa may have an even greater positive impact in
health plans with a younger population.
STROKE—Methods & Concepts
PST5
PROMOTING THE IMPROVEMENT OF STROKE CARE AT THE
STATE-LEVEL: CREATING A LEGISLATIVE POLICY REPORT
LINKED TO AN EVIDENCE-BASED SIMULATION MODEL
Matchar DB1, Samsa GP1, Sissine ME1, Howard G2,
Warhadpande DS1
1Duke University, Durham, NC, USA, 2University of Alabama at
Birmingham, Birmingham, AL, USA
OBJECTIVES: Health policy decision makers prefer to make
decisions with accurate estimates of the burden of the target
problem and the likely outcome of various policy options. Cre-
ating these estimates involves collecting, synthesizing, and com-
municating complex data. Simulation models provide a useful
approach for integrating complex data for producing compelling
reports. This project utilized a simulation model in the produc-
tion of a legislative document reporting on the impact of
improved stroke services in Mississippi (MS). METHODS: The
research team met with various stakeholders in stroke care
within MS, to identify a target policy issue for the legislative
report. Based on interests of MS stroke researchers, advocates,
clinicians, and policy experts, we identiﬁed the following issue:
improvements in stroke care through the use of an existing
telemedicine infrastructure as a target issue, with attention to
impact on Medicaid costs. We modiﬁed the Duke Stroke Policy
Model (DSPM), a Markov model of stroke development and
outcome to incorporate MS risk factors (from the REGARDS
survey), costs (from Medicare), and current stroke services (from
the MS Stroke Report 2005). Estimates of health and economic
impacts aimed at improving stroke care were incorporated into
an illustrative legislative report. RESULTS: The DSPM-based
report was generated as above. The illustrative report has been
reviewed by stakeholders in state policy for comment. The report
is perceived as easy-to-read and informative. CONCLUSION:
Bridging the gap between evidence and policy making will
require innovative and efﬁcient approaches to linking existing
data to produce compelling reports. This application of the
DSPM provides “proof of concept” of one approach based on
the use of a general purpose simulation model of stroke. We
believe that this is a promising strategy and will work to expand
our efforts to other states and a broader range of stroke policy
issues.
STROKE—Patient-Reported Outcomes
PST6
GENERIC AND DISEASE-SPECIFIC HEALTH RELATED
QUALITY OF LIFE (HRQOL) IN STROKE SURVIVORS
Wasserman J, Ostwald SK, Godwin KM
University of Texas-Houston School of Nursing, Houston,TX, USA
OBJECTIVES: To measure and compare generic and disease-
speciﬁc HRQoL in stroke survivors one to two years post hos-
pital discharge. METHODS: The SF-36 and the Stroke Impact
Scale (SIS) were administered to 33 stroke survivors. The stan-
dard gamble method was used to elicit utilities regarding stroke
health states. RESULTS: Of the 33 patients, 79% were male,
67% had mild stroke, 24% had moderate stroke, and 9% had
severe stroke; mean age was 66.9. Study participants scored sig-
niﬁcantly lower (p < 0.05) than the general population on seven
of the eight multi-item scales of the SF-36: Physical Functioning,
Role-Physical, General Health, Vitality, Social Functioning,
Role-Emotional, and Mental Health. Participants scored signiﬁ-
cantly lower (p < 0.001) than the general population on both
physical and mental health component summary measures.
Using the SIS, participants had a mean score of 57.23 on the
physical summary score. On the four component scales of the
physical summary score, participants had mean scores of: 44.14
on Strength, 50.31 on Hand Strength, 65.93 on Mobility, and
71.26 on Activities of Daily Living (ADL). Participants had mean
scores of 79.55 on Memory, 85.91 on Communication, 73.18
on Emotional, and 57.68 on Social Participation. SIS Physical
was signiﬁcantly correlated (p < 0.05) with both SF-36 physical
measures. Both the SF-36 mental component scores and Mental
Health domain measure were signiﬁcantly correlated with the SIS
measures of ADL, Memory, Communication, Emotional, and
Social Participation (p < 0.05). The mean standard gamble utility
score for all participants was 83.2. CONCLUSION: Stroke sur-
vivors one to two years post stroke had signiﬁcantly lower scores
than the general population on most of the SF-36 health domains
with the exception of bodily pain. Positive correlations with
major domains of the disease-speciﬁc SIS indicate that the SF-36
was sensitive to stroke health states. Further research with 
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a larger sample size and severity sub-group comparisons is
ongoing.
PST7
DOES ADMINISTRATION MODE AFFECT ITEM HIERARCHY 
IN STROKE SPECIFIC QUALITY OF LIFE MEASURE,
STROKE IMPACT SCALE?—TELEPHONE AND MAIL
ADMINISTRATION METHODS
Kwon S,Velozo C, Duncan P
University of Florida, Gainesville, FL, USA
OBJECTIVES: The purpose of this study is to further examine
potential mode effect on item difﬁculty hierarchy by taking item
response theory (IRT) approach. Speciﬁc objective is to examine
if the Stroke Impact Scale-16 (SIS-16) items function in the same
way between the two administration modes in item difﬁculty
hierarchy. METHODS: Patients with stroke were identiﬁed using
ICD-9CM in 13 participating Veterans Affairs (VA) hospitals in
administrative database and conﬁrmed by reviewing electronic
medical records. Patients were randomized to mail or telephone
groups to administer SIS-16 at 12-weeks after stroke. Baseline
demographics and severity of stroke were compared. Item difﬁ-
culties and errors associated with the difﬁculties were estimated
with the Rasch model using Winsteps. RESULTS: Telephone and
mail group are composed of 96 and 92 patients, who were com-
parable in terms of demographics and stroke severity. SIS-16
scores distributed without severe ceiling or ﬂoor effects. The
‘walk fast’ was the most difﬁcult and ‘stay sitting without losing
balance’ was the easiest item. The item difﬁculty hierarchy was
maintained in 10 items, but three items, carry heavy object with
affected hand, dress the top part, move from bed to chair, were
as more difﬁcult in telephone survey while reported walk one
block, control bladder, get to the toilet were more difﬁcult in the
mail administration group. However, considering the error asso-
ciated with the difﬁculty showed that all 16 items were within
95% conﬁdence intervals, thereby failing to show signiﬁcant 
Differential Item Functioning (DIF). CONCLUSION: While the
items of the SIS-16 showed some discordance in item hierarchy
across mail and telephone administrations, none of the items
showed signiﬁcant DIF. These ﬁndings suggest that the mode of
administration does not inﬂuence item difﬁculty hierarchies. As
technologies such as internet and emails are more accessible, a
research agenda needs to be developed to facilitate efﬁcient
follow-up.
SURGERY—Cost Studies
PSU1
COST OF COMPLICATIONS ASSOCIATED WITH TOTAL KNEE
REPLACEMENT AND TOTAL HIP REPLACEMENT
Campbell HM, Raisch DW,Taylor Z
Department of Veterans Affairs Cooperative Studies Program
CRPCC, Albuquerque, NM, USA
OBJECTIVES: Literature incorporating costs of total knee
replacement (TKR) and total hip replacement (THR) other than
inpatient care, follow-up after 90 days, or complications besides
deep vein thrombosis (DVT) and pulmonary embolism (PE) is
lacking. Our objective was to determine the impact of TKR and
THR complications on inpatient and outpatient direct medical
costs over 1 year in the Department of Veterans Affairs (VA).
METHODS: Nationwide VA data were utilized. Direct medical
costs were determined from VA costing methodologies. Utiliza-
tion included labs, x-rays, medications, and inpatient, outpa-
tient, and emergency department visits associated with surgery
or its complications. Complications included DVT, PE, major
hemorrhage (MH), and thrombocytopenia. Mann-Whitney U
tests of median costs were performed by complication within
TKR and THR. RESULTS: The VA spent $121,305,992 caring
for 5309 patients (3424 TKR and 1885 THR). TKR patients
who developed DVT (n = 116) or PE (n = 21) had higher median
(mean ± standard deviation) costs: $17,572 ($21,638 ± $26,942)
versus $14,850 ($17,889 ± $7944, n = 3308, p = 0.001) and
$17,912 ($22,920 ± $17,282) versus $14,882 ($17,985 ± $9189,
n = 3403, p = 0.041), respectively. No differences were found
between TKR patients with MH or thrombocytopenia or
between THR patients with DVT or MH compared to those
without these complications. THR patients who had PE (n = 22)
or thrombocytopenia (n = 19) incurred higher costs: $18,719
($22,833 ± $12,753) versus $16,277 ($18,854 ± $8894, n =
1863, p = 0.046) and $19,831 ($22,740 ± $11,930) versus
$16,277 ($18,861 ± $8914, n = 1866, p = 0.046), respectively.
CONCLUSION: Complications resulted in signiﬁcantly higher
costs, which may reﬂect earlier mortality due to complications.
Lack of health care information from non-VA organizations is a
potential limitation.
SURGERY—Methods & Concepts
PSU2
COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN THE
TREATMENT OF OPEN TIBIA FRACTURES IN SWEDEN 
AND DENMARK
Alt V1, Chhabra A2, Nicklasson L3, Greenberg D4, Schnettler R5
1University Hospital Giessen-Marburg, Site Giessen, Giessen, Germany,
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Israel, 5University Hospital Giessen, Giessen, Germany
OBJECTIVES: Recombinant human bone morphogenetic
protein (rhBMP2) is a novel biologic therapy that promotes bone
growth at the fracture site. We analyzed the cost-effectiveness of
rhBMP-2 in open tibia fractures in Sweden and Denmark.
METHODS: We developed an economic model to compare
rhBMP-2 + standard of care (soft tissue management and
intramedullary nailing) with standard of care alone. We obtained
clinical data from the BMP-2 Evaluation for Surgery in Tibial
Trauma (BESTT) trial and estimated treatment costs from
national sources such as NORD-DRG for Sweden and DkDRG
for Denmark. Total cost were measured as direct cost plus indi-
rect costs and reported separately. Direct costs were measured as
drug costs plus cost for complications and indirect costs were
valued as lost productivity using average annual salaries. We
assigned utility weights to different grades (Gustillo I–IIIB) of
open tibia fractures to estimate the difference in quality-adjusted-
life-expectancy. We performed the analysis from the health care
payer’s and societal perspectives for a one-year time-horizon. We
focus our analysis on Gustillo grade III (A and B) fractures where
rhBMP-2 is most commonly used. RESULTS: In Sweden, use of
rhBMP-2 (€2800) for grade III open tibia fractures resulted in
an incremental cost of €1684 per patient and in incremental cost-
effectiveness ratio (ICER) of €22,811/QALY. When indirect costs
were included, rhBMP-2 was cost-saving. In Denmark, rhBMP-
2 (€3100) treatment for grade III open tibia fractures resulted in
an incremental cost of €1635 per patient and an ICER of
€17,964/QALY and was cost-saving when productivity loss was
also included. CONCLUSION: From a payer’s perspective,
rhBMP-2 is a cost-effective treatment option in grade III open
tibia fractures for both the Swedish and Danish health care
systems. rhBMP-2 was a cost-saving option from the societal per-
spective, and therefore, a good value for money.
